University of Rochester

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of Rochester sits in the top decile of US sponsors by registered trial count (#53 of 15,742 sponsors by registered trial count).

636 total trials 94 currently recruiting 448 completed early-phase tilt top decile by trial count

University of Rochester: 636 sponsored US clinical trials, 94 recruiting.

University of Rochester sponsors 636 registered US clinical trials on ClinicalTrials.gov, 94 of them currently recruiting, and 448 completed. 54 of these trials are in Phase 3-4 (later-stage) and 147 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cancer, with 7 trials.

Top-decile sponsor footprint

University of Rochester ranks in the top decile of sponsors by registered trial count (#53 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 61/100

448 of 506 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

636 total, page 13 of 13

COMPLETED Phase 3

Trial of Mifepristone for Fibroids

NCT00133705

COMPLETED Phase 2

National Institute of Neurological Disorders and Stroke (NINDS) Parkinson's Disease Neuroprotection Trial

NCT00063193

COMPLETED Phase 1

Comparison of Two Psychotherapy Treatments for Depressed Women With a History of Sexual Abuse

NCT00257400

COMPLETED Phase 3

Maternal Problem-Solving in Childhood Cancer

NCT00234793

COMPLETED Phase 1

Emergency Linkage to Outpatient Psychiatric Services

NCT00278811

COMPLETED Phase 2

Improving Outcomes of Hospitalized Elders and Caregivers

NCT00178412

COMPLETED Phase 4

Escitalopram Treatment of Patients With Agitated Dementia

NCT00260624

COMPLETED NA

Prehospital Screening to Prevent Injury and Illness

NCT00382655

COMPLETED NA

Improving Asthma Care for Very Low Birth Weight Infants

NCT00156507

COMPLETED Phase 2

Buspirone in Reducing Shortness of Breath in Patients With Cancer

NCT00053846

COMPLETED NA

Vulvar Vestibulitis Clinical Trial: Desipramine-Lidocaine

NCT00276068

COMPLETED Phase 1

Music Therapy During Botulinum Injections

NCT00178217

COMPLETED Phase 4

Gabapentin Versus Estrogen for the Treatment of Hot Flashes

NCT00276081

COMPLETED Phase 2

Trial of Chemotherapy Followed by Pulsed Docetaxel and Concurrent Radiation for Non-Small Cell Lung Cancer

NCT00167401

TERMINATED

The Long Term Impact of Initiating Pramipexole Versus Levodopa in Early Parkinson's Disease (CALM-PD Cohort Study)

NCT00804479

TERMINATED NA

Study of Breath-holding as a Means to Reduce Tumor Motion From Breathing

NCT00178477

COMPLETED NA

Omega-3 Fatty Acids in Children and Adolescents With Bipolar Disorder

NCT00252486

COMPLETED NA

Educational/Behavioral Intervention Program for Parents of Premature Infants

NCT00120614

COMPLETED Phase 2

Donor Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Relapsed or Refractory Metastatic Kidney Cancer

NCT00262886

COMPLETED NA

A Study For Using Radiosurgery On Limited Metastases

NCT00178399

COMPLETED

Neural Changes in the Aging Auditory System

NCT00264407

COMPLETED NA

Health-e-Access Telemedicine in Primary Pediatric Care

NCT00234806

COMPLETED NA

Study for Using Radiosurgery on Limited Metastases of Breast Cancer

NCT00167414

COMPLETED NA

Patient Education in Preventing Nausea and Vomiting in Cancer Patients Receiving Chemotherapy

NCT00005994

COMPLETED NA

Conditioning, the Placebo Effect, and Psoriasis

NCT00005922

COMPLETED

Radiation-Induced Cytokine Cascades and Their Correlation With Central Nervous System Injury

NCT00178295

COMPLETED NA

Effect of Androgen Suppression on Bone Loss in Patients With or Without Bone Metastases Secondary to Prostate Cancer

NCT00003903

COMPLETED Phase 1

Interferon Gamma in Treating Patients With Recurrent or Metastatic Melanoma or Other Solid Tumors

NCT00004016

COMPLETED Phase 1

Pulsed Paclitaxel And Daily Thoracic Radiotherapy For Inoperable (Stage I/II) Or Unresectable Lung Cancer

NCT00178256

COMPLETED Phase 1

Rituximab Plus Interleukin-2 in Treating Patients With Lymphoma

NCT00003356

COMPLETED NA

In Home Hospital Care Program

NCT00234780

COMPLETED

Circulating Cytokines as Predictors of Radiation Induced Pulmonary Toxicity

NCT00178230

COMPLETED

Long QT Syndrome-Population Genetics and Cardiac Studies

NCT00005176

COMPLETED Phase 1

Feasibility of Treatment of Cancer Involving the Liver With High Dose Radiation

NCT00178243

COMPLETED Phase 1

Parallel Group, Placebo-Controlled, Tolerability, Safety, and Efficacy Study of OPC-14117 in HIV Dementia

NCT00002148

COMPLETED

Measuring Alterations of DNA in Human Blood

NCT00178308

← Previous Page 13 of 13

Phase Distribution

PhaseTrial count
Phase 1 66
Phase 2 81
Phase 3 20
Phase 4 34

What is open in the University of Rochester pipeline

94 recruiting of 636 indexed (15% open); 448 completed (70%).

Phase mix: 54 late (III/IV) vs 147 early (I/II) (early-phase heavy).

Top condition: Cancer (7 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of Rochester: open-pipeline peers nationwide

Peers matched on 636 registered trials and 15% open enrollment, not the therapeutic-area sidebar.

University of Rochester sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0200400600800 0%5%10%15%20% Total trials Recruiting share University of RochesterUS Department of Veterans AffairsUniversity of Southern CaliforniaBaylor College of MedicineUniversity of California, DavisLoma Linda UniversityDompé Farmaceutici S.p.AVanderbilt-Ingram Cancer CenterBrown University
University of Rochester sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of Rochester sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 636 trials (± recruiting share)

Sponsors near 15% open enrollment (± trial volume)

What to do with this University of Rochester page

636 registered trials is a research-attention snapshot, not an endorsement of University of Rochester or any single study.

  • 94 of University of Rochester's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Cancer is the condition University of Rochester studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Rochester pipeline card: 636 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.